United States Patent 11,530,408: Claim Scope, RNAi Patent Landscape, and Generic Entry Risk

U.S. Patent No. 11,530,408 covers structurally asymmetric small interfering RNA duplexes, particularly duplexes with one blunt end, one overhang, and engineered terminal base-pair stability. The independent claims are composition claims rather than target-specific method-of-use claims. They can therefore reach RNAi agents directed to multiple genes if the duplex architecture satisfies the claimed sequence, terminal-pairing, and end-structure limitations.

The principal commercial risk is platform-level coverage. A product may infringe without using a sequence disclosed in the patent if its duplex has the claimed asymmetric architecture and terminal instability. The claims do not, on their face, require a particular therapeutic target, disease, conjugate, formulation, delivery vehicle, or manufacturing process.

What does U.S. Patent 11,530,408 protect?

The patent protects an iRNA duplex having four core characteristics:

Two complementary or substantially complementary strands.
A first and second monomer located within the first three to six positions from an end of the strands.
A difference in pairing stability between the two strands and the stability of one or both strands pairing with the target sequence.
A blunt end at one end of the duplex and an overhang at the other end.

The claimed architecture is designed to create strand-selection asymmetry. The antisense strand is intended to load preferentially into the RNA-induced silencing complex, or RISC, while reducing the likelihood that the sense strand becomes the active guide strand.

Claim 1 is the broadest independent claim. Claim 6 is a second independent claim that imposes a specific P-1 terminal condition involving adenine, uracil, or a modified base that pairs with one of those nucleobases.

Core structural limitations

Claim element	Scope
Molecular class	iRNA duplex
Strand configuration	Sense and antisense strands
Strand length	Claims 15-17 narrow the range to 15-30, 19-25, or 21/23 nucleotides
Duplex ends	One blunt end and one overhang
Overhang limitation	Claim 14 and claim 20 specify a two-nucleotide 3′ overhang on the antisense strand
Terminal pairing	A/U, G/U, I/C, mismatches, and specified modified-base pairs
Stability relationship	Duplex-forming pairing must differ in stability from target-pairing
Target requirement	No particular gene, mRNA, disease, or target sequence is recited
Chemical modification	Sugar and base modifications are expressly contemplated
Delivery system	No GalNAc, lipid nanoparticle, conjugate, or other delivery system is required

How broad are claims 1 and 6?

Claim 1 combines a functional stability limitation with a defined duplex-end arrangement. It does not require the stability difference to be quantified by a melting temperature, free-energy threshold, assay, or specific thermodynamic model. That language may provide broad coverage, but it also creates claim-construction and enablement issues because infringement analysis may require identifying the relevant pairing and demonstrating that its stability differs from the target duplex pairing.

Claim 6 is narrower in one respect. It requires the P-1 subunit at the 5′ end of the antisense strand to be A, U, or a modified base that pairs with A or U. Claim 18 narrows the P-1 pair further to an A:U pair.

The claims are not limited to canonical Watson-Crick duplexes. Claims 2-5 and 9 cover G:U pairs, I:C pairs, mismatches, and A:U pairings in the terminal positions. Claims 7-9 also cover modified or nonstandard pairings, including:

2-amino-A:U;
2-thio-U;
5-methyl-thio-U:A;
G-clamp:G;
guanidinium-G-clamp:G;
pseudouridine:A; and
pairings involving sugar-modified subunits.

This drafting strategy attempts to prevent circumvention through routine nucleobase or sugar modification.

What formulations are protected by U.S. Patent 11,530,408?

The patent claims the RNAi duplex itself, not a finished pharmaceutical formulation. A formulation containing an infringing duplex may create product-level exposure, but the claims supplied do not require:

a pharmaceutically acceptable carrier;
a particular buffer;
a lipid nanoparticle;
a conjugated ligand;
a GalNAc moiety;
a polymeric delivery system;
a specific route of administration; or
a particular dosage form.

The formulation is relevant to infringement only because the active RNA duplex may be incorporated into the formulation. Separate formulation patents could cover particle composition, conjugation chemistry, excipients, stability, or administration.

What are the principal dependent-claim limitations?

Claims	Limitation
2	Terminal pairs independently selected from A:U, G:U, I:C, or mismatched pairs
3	G:U pairs in P-4 through P-1
4	A:U pairs in P-5 through P-1
5	A:U pairs in P-3 through P-1
7	Defined canonical, noncanonical, modified-base, and sugar-modified pairs in P5 through P1
8	G:C pairs in P1 through P4
9	Combined destabilized terminal region and stabilized opposite region
10-13	Reduced target-pairing stability and specified mismatch types
14	Blunt 5′ antisense end and two-nucleotide 3′ antisense overhang
15-17	Defined strand lengths
18	A:U at P-1
19-20	Blunt-end/overhang structure, including the two-nucleotide antisense overhang

Claims 10-13 are commercially important because they introduce a second form of asymmetry. The claimed destabilization may occur in the pairing between a strand and its target, rather than only in the duplex itself. Claim 13 expressly identifies U:U, G:G, G:A trans, G:A cis, and G:U noncanonical pairings.

How would infringement analysis apply to an siRNA product?

A product-by-product analysis would begin with the duplex architecture rather than the therapeutic target.

Likely infringement checkpoints

Determine which strand is designated as sense and which is antisense.
Map the 5′ and 3′ termini.
Confirm whether one end is blunt and the other has an overhang.
Identify P-5 through P5 and the relevant terminal pairings.
Determine whether an A:U, G:U, mismatch, or modified equivalent is present.
Analyze the P-1 position, particularly for claim 6 and claim 18.
Measure or otherwise establish the claimed stability difference.
Confirm strand lengths under claims 15-17.
Evaluate whether a chemical modification falls within the express modified-base or sugar-modification language.
Review prosecution-history amendments and arguments before relying on the broadest literal construction.

The most difficult limitation is likely the stability relationship. A competitor may argue that the claim requires a demonstrated difference in thermodynamic stability and cannot be satisfied solely by the presence of a particular terminal base pair. The patent owner may argue that the sequence and pairing arrangement itself establishes the claimed difference.

How does the patent compare with conventional siRNA design?

Conventional siRNA products often use a 19-base-pair duplex with two-nucleotide 3′ overhangs on both strands. The claims here are more specific in several respects.

Design characteristic	Conventional siRNA	Patent 11,530,408
Ends	Often two 3′ overhangs	One blunt end and one overhang
Strand selection	May rely on general thermodynamic asymmetry	Requires claimed terminal stability relationship
Terminal pairs	Often canonical	Expressly covers noncanonical and modified pairs
Target	Product-specific	No target required by independent claims
Length	Commonly about 19-23 nucleotides	Claims 15-17 specify ranges and 21/23 architecture
Modifications	Product-dependent	Sugar and base modifications are included in dependent claims
Delivery	Separate technology	Not required by the claims

A standard duplex with two overhangs at opposite ends may fall outside claims 1 and 6 because the claims require a blunt end and an overhang. A duplex with one blunt end and one overhang remains potentially relevant even if it uses a different therapeutic sequence.

What is the Orange Book status of U.S. Patent 11,530,408?

The supplied claims are platform composition claims and do not identify an approved drug, active ingredient, dosage form, or method of use. A patent is not automatically an Orange Book-listed patent merely because it covers a pharmaceutical technology.

The FDA Orange Book generally records patents submitted for approved drug products under applicable listing categories. A platform patent covering an unapproved RNA duplex, without a product-specific listing tied to an approved drug application, does not establish Orange Book protection for a particular siRNA product (FDA, 2024).

Accordingly, the patent number alone does not create an Orange Book-listed patent defense or an automatic Paragraph IV pathway. For an approved RNAi product, the relevant inquiry is whether the sponsor listed this patent against that product and whether the FDA accepted the listing.

When does U.S. Patent 11,530,408 lose exclusivity?

The claims supplied do not disclose the patent’s expiration date, patent-term adjustment, patent-term extension, terminal disclaimer, or any disclaimer affecting term. Those dates must be determined from the USPTO patent-term record and the patent’s priority chain, not from the claims.

The ordinary statutory framework provides a 20-year term measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory rules (35 U.S.C. §§ 154, 156). A priority application does not necessarily determine the expiration date without reviewing the complete family and continuation history.

The patent’s enforceability also depends on maintenance-fee status, reexamination, post-grant proceedings, terminal disclaimers, and court decisions. A patent can remain within its nominal term but become unenforceable or be narrowed through later proceedings.

Which companies are most exposed to this patent class?

The greatest exposure is among companies developing chemically modified siRNA products with:

asymmetric blunt-end/overhang geometry;
21- or 23-nucleotide strand designs;
A:U or G:U terminal pairs;
intentional guide-strand thermodynamic asymmetry;
mismatched target-site interactions; or
modified bases incorporated at the terminal positions.

Potentially affected developers include RNAi companies, large pharmaceutical licensees, oligonucleotide manufacturers, and contract development and manufacturing organizations that supply the active duplex. The patent does not depend on a specific delivery platform, so both conjugate-based and nanoparticle-based products could be relevant if their duplexes satisfy the limitations.

What generic launch risks exist?

The patent presents a higher risk for an authorized generic or follow-on siRNA that copies the reference product’s duplex architecture. The risk is lower where the challenger uses:

two overhanging ends;
a fully blunt duplex;
different terminal pairings;
a different antisense terminal configuration;
strand lengths outside the claimed ranges; or
a demonstrably different stability profile.

For an approved RNAi product, a challenger could pursue a Paragraph IV certification only if the patent is listed in the Orange Book and otherwise qualifies for certification. If the patent is not listed, the challenger may need to address infringement through a declaratory-judgment action, a negotiated license, or post-launch litigation.

RNAi products are not biosimilars merely because they are biologically active. A follow-on siRNA is generally analyzed under the applicable drug pathway, often involving an abbreviated application or 505(b)(2) strategy, depending on the product and regulatory record. The patent claims themselves do not create biosimilar exclusivity.

What litigation and settlement issues should be reviewed?

The key litigation questions are:

whether the asserted claim requires a measurable thermodynamic difference;
whether “first monomer” and “second monomer” have a fixed strand orientation;
whether a chemically modified base is a claimed equivalent;
whether one blunt end and one overhang must occur at specified strands;
whether the target-pairing limitation is satisfied by a mismatch outside the active cleavage region;
whether prosecution history limits the claims to specific terminal positions; and
whether the patent is subject to a terminal disclaimer or related-family estoppel.

Any settlement involving this patent would likely address product-specific launch dates, licensed sequences, permitted chemical modifications, delivery platforms, and rights to future continuation patents. A settlement of unrelated Alnylam, Arrowhead, Silence Therapeutics, Ionis, or other RNAi litigation would not by itself establish freedom to operate under this patent.

How strong is the patent estate?

The claims have meaningful breadth because they are target-independent and cover chemical modifications. Their practical strength is moderated by several limitations:

Strength	Constraint
Target-independent composition claims	Requires specific blunt/overhang architecture
Covers multiple noncanonical pairings	Stability limitation may require technical proof
Includes modified bases and sugars	Claim scope may depend on prosecution history
Covers 15-30 nucleotide strands in dependent claims	Many products can design outside the narrower ranges
Applies across delivery platforms	Does not cover delivery or formulation by itself
Two independent claims	Claim 6 has a narrower P-1 requirement

The strongest assertion position would generally involve a duplex with a blunt 5′ antisense end, a two-nucleotide 3′ antisense overhang, 21- and 23-nucleotide strands, and A:U or G:U terminal pairings. A product that departs from the claimed end geometry or terminal pairing has a stronger design-around position.

Key Takeaways

U.S. Patent 11,530,408 is directed to asymmetric iRNA duplex architecture.
Claims 1 and 6 are target-independent composition claims.
The central limitations are one blunt end, one overhang, and a defined difference in pairing stability.
Claims 14 and 20 focus on a blunt 5′ antisense end and a two-nucleotide 3′ antisense overhang.
Claims 15-17 target common 19-25 nucleotide siRNA formats, including 21/23-nucleotide designs.
The patent expressly reaches several noncanonical base pairs and chemically modified subunits.
The claims do not independently cover GalNAc conjugation, lipid nanoparticles, formulation excipients, or manufacturing methods.
Orange Book status must be assessed against a particular approved drug application.
Paragraph IV exposure depends on product-specific listing and application strategy.
The principal design-around options are altered end geometry, terminal pairing, strand length, and stability profile.
Exact patent expiration requires the USPTO term record and complete priority chain.

FAQs About U.S. Patent 11,530,408

Does the patent cover all siRNA duplexes?

No. The claims require the specified asymmetric end structure and terminal stability relationship. A conventional duplex with two overhangs may fall outside the independent claims.

Does changing the siRNA target avoid infringement?

Not necessarily. The independent claims do not recite a particular target gene or disease. Changing only the target sequence may not avoid infringement if the duplex architecture remains within the claims.

Does a GalNAc conjugate avoid the patent?

No. GalNAc conjugation is not required by the claims, but it also does not remove an infringing duplex from the claims if the underlying RNA structure satisfies the limitations.

Are RNAi products subject to biosimilar patent litigation?

Usually not under the biosimilar framework merely because they use RNA interference. Follow-on RNAi products are generally evaluated under the regulatory pathway applicable to the particular drug and reference product.

Can a two-nucleotide overhang eliminate infringement?

It depends on its location. Claim 14 and claim 20 specifically cover a two-nucleotide overhang at the 3′ end of the antisense strand when paired with the claimed blunt-end arrangement. A two-nucleotide overhang at another position may produce a different result.

References

U.S. Patent No. 11,530,408. (2023). Interfering RNA molecules with asymmetric ends. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
United States Code. (2024). 35 U.S.C. § 154, patent term.
United States Code. (2024). 35 U.S.C. § 156, patent term extension.
United States Patent and Trademark Office. (2024). Patent Center and patent term adjustment information. U.S. Department of Commerce.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	479752	⤷ Start Trial
Australia	2004220556	⤷ Start Trial
Australia	2004227414	⤷ Start Trial
Australia	2004229519	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,530,408

Summary for Patent: 11,530,408